Eptifibatide Powder Cas No.188627-80-7
Specification: ≥99%
CAS No.: 188627-80-7
Molecular Formula: C₃₅H₄₉N₁₁O₉S₂
Molecular Weight: 831.96 g/mol
Test Method: HPLC
Active Ingredient: Eptifibatide (a cyclic heptapeptide)
Characteristics: White or off-white solid powder
Packaging: 1-100g; 1kg/foil bag; 25kg/drum
Storage Condition: Store in a cool, dry place sealed container protected from light and moisture
Shelf Life: 24 months
Declaration of Use: This product is intended for industrial use or scientific research only.
Eptifibatide API Powder CAS 188627-80-2
Why Is Eptifibatide The Gold Standard GP IIb/IIIa Receptor Antagonist?
1. Product Characterization & Formulation Value
Xi'an Tihealth manufactures high-purity Eptifibatide API, a synthetic, disulfide-linked cyclic heptapeptide designed specifically for intravenous antithrombotic formulations. Functioning as a highly competitive and reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, it represents a critical active pharmaceutical ingredient for mitigating acute ischemic events during percutaneous coronary interventions (PCI).
Peptide synthesis at a commercial scale requires uncompromising control over related impurities. Our solid-phase peptide synthesis (SPPS) and subsequent advanced reverse-phase HPLC purification protocols ensure that our Eptifibatide API consistently exceeds 99.0% purity. We rigorously control trifluoroacetic acid (TFA) residues, moisture content, and bacterial endotoxins, delivering a sterile-grade precursor ideal for the compounding of generic acute coronary syndrome (ACS) injectables.
2. Technical Data Sheet (TDS) & Specifications
| Quality Parameter | Pharmaceutical Specification Standard (EP / USP) |
|---|---|
| Sequence | Mpa-Har-Gly-Asp-Trp-Pro-Cys-NH2 (Disulfide bridge: 1-7) |
| Assay / Purity (HPLC) | ≥ 99.0% |
| Peptide-Related Impurities | Individual Impurity ≤ 0.50%; Total Impurities ≤ 1.0% |
| Physical Appearance | White to off-white lyophilized powder |
| Water Content (Karl Fischer) | ≤ 8.0% |
| Acetate Content (HPLC) | 5.0% - 15.0% (Supplied as Eptifibatide Acetate salt) |
| TFA (Trifluoroacetic Acid) Residue | ≤ 0.25% (Strictly controlled via ion exchange) |
| Bacterial Endotoxins | ≤ 5.0 EU/mg (Suitable for parenteral formulation) |
3. Pharmacological & Receptor Binding Mechanisms
High-Affinity KGD Motif Recognition
Unlike non-specific inhibitors, Eptifibatide is modeled after barbourin, a protein found in rattlesnake venom. It utilizes a highly specific Lys-Gly-Asp (KGD) amino acid sequence motif to selectively bind the GP IIb/IIIa receptor on activated platelets, preventing fibrinogen cross-linking and subsequent thrombus aggregation.
Rapid Reversibility Profile
In acute cardiac care, managing bleeding risks is paramount. Eptifibatide exhibits a highly favorable pharmacokinetic profile: it is a reversible antagonist. Following the cessation of intravenous infusion, platelet function and normal hemostasis recover rapidly (typically within 4 hours), offering precise clinical control.
4. Core Pharmaceutical Applications
- Acute Coronary Syndrome (ACS) Injectables: Serves as the primary active pharmaceutical ingredient for intravenous solutions used in the medical management of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI).
- Percutaneous Coronary Intervention (PCI): Formulated into sterile IV drips to prevent ischemic complications and stent thrombosis during balloon angioplasty and stent placement procedures.
- Cardiovascular Formulation R&D: Utilized in laboratory environments for generic bioequivalence studies and the development of novel peptide-based antithrombotic delivery systems.
5. Frequently Asked Sourcing Questions
What are the cold chain storage and shipping requirements for Eptifibatide API?Hot Tags: eptifibatide powder cas no.188627-80-7, China eptifibatide powder cas no.188627-80-7 manufacturers, suppliers, factory, tranexamic powder
You Might Also Like
Send Inquiry